Skip to main content
OpenTrials
Completed

NCT Number: NCT00153062

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one.

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

9.159.1331 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male or female subjects 55 year or older who have suffered an ischemic stroke within the past 90 days and who meet all other inclusion criteria. Include also patients of ages 50 - 54 years and/or 90 to 120 days after the qualifying stroke provided the patient has at least two of the following additional risk factors:

  • Diabetes mellitus
  • Hypertension (systolic BP ¿ 140 or diastolic BP ¿ 90)
  • Smoker at time of qualifying stroke
  • Obesity (BMI>30; BMI=weight (kg)/[height (m)]2)
  • Previous vascular disease (stroke, MI, or peripheral arterial disease prior to qualifying stroke)
  • End-organ-damage (retinopathy, LVH, or microalbuminuria)
  • Hyperlipidemia

Exclusion criteria

hemorrhagic stroke (must be ruled out by imaging);unable to give informed consent; known brain tumor, severe renal or hepatic insufficiency, current active peptic ulcer disease, severe coronary artery disease including unstable angina pectoris or an MI within the previous 3 months,or history of a hemostatic disorder or systemic bleeding ;hyperkalemia;uncorrected volume or sodium depletion; pre-stroke history of dementia;modified Rankin score greater than 4;qualifying stroke induced by surgical or cardiovascular procedure;uncontrolled hypertension at entry above 180/110 mmHg (goal BPs are lower); SBP 120 mmHg or less for hospitalized patients; currently taking an ARB and not able or willing to switch to alternative; required or planned continuing treatment with antithrombotics or anticoagulants including heparin or warfarin or non-study platelet inhibitors; syndrome of asthma, rhinitis and nasal polyps;scheduled for major surgery, carotid endarterectomy, or carotid angioplasty (4 weeks post surgery is allowed);unlikely to be released from hospital following the qualifying stroke or presence of a severe disability likely to lead to being bedridden or demented or a non-vascular disease or condition which makes it unlikely that the patient will survive to the end of the trial; history of thrombocytopenia or neutropenia.

Treatment and study plan

Aggrenox

Drug

25mg aspirin, 200 mg dipyridamole

clopidogrel placebo

Drug

placebo

Micardis

Drug

80 mg micardis

Aggrenox placebo

Drug

placebo

clopidogrel

Drug

75 mg clopidogrel

Micardis placebo

Drug

placebo

Primary outcomes

  1. Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only)

    Time frame: time since randomization; follow-up period is 1.5 to 4.4 years

  2. Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only)

    Time frame: time since randomization; follow-up period is 1.5 to 4.4 years

Secondary outcomes

  1. Composite Outcome of Stroke, Myocardial Infarction (MI), or Vascular Death (Antiplatelet Comparison Only)

    Time frame: time since randomization; follow-up period is 1.5 to 4.4 years

    Number of patients with any of stroke, myocardial infarction, vascular death

  2. Composite Outcome of Stroke, Myocardial Infarction, Vascular Death, or New or Worsening Congestive Heart Failure (CHF) (Telmisartan vs. Placebo Only)

    Time frame: time since randomization; follow-up period is 1.5 to 4.4 years

    Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure

  3. Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only)

    Time frame: Randomization to final patient contact

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Collaborators

  • Bayer
  • GlaxoSmithKline

Registry information

Official study title

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis

Important dates

Study start
2003
Primary completion
2008
First posted
Sep 12, 2005
Registry last updated
May 13, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.